LIGHT/TNFSF14 Protein, Human, Recombinant (hFc)

LIGHT/TNFSF14 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 44.9 kDa and the accession number is AAK26160.1.

Pack Size	Availability	Price/USD	Quantity
100 μg	5 days	$ 539.00
1 mg	5 days	$ 3,520.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 539.00

1 mg

5 days

$ 3,520.00

Description

LIGHT/TNFSF14 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 44.9 kDa and the accession number is AAK26160.1.

Species	Human
Expression System	HEK293 Cells
Tag	N-hFc
Accession Number	AAK26160.1
Synonyms	HVEML, CD258, LIGHT, tumor necrosis factor (ligand) superfamily, member 14, TR2, LTg
Construction	The Human TNFSF14 (AAK26160.1) (Asp74-Val240) was expressed with the Fc region of Human IgG1 at the N-terminus.
Protein Purity	> 90 % as determined by SDS-PAGE.
Molecular Weight	44.9 kDa (predicted)

Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	LIGHT, also known as TNFSF14 or CD258, is a newly identified member of the TNF superfamily (TNFSF14) that is expressed by activated T lymphocytes, monocytes, granulocytes, spleen cells, and immature dendritic cells. TNFSF14 / LIGHT / CD258 is a type II transmembrane protein that is known to bind 2 membrane-bound TNFSF signaling receptors: HVEM, which is predominantly expressed by T cells, and lymphotoxin β receptor (LTβR), which is expressed by stromal cells and nonlymphoid hematopoietic cells. TNFSF14 / LIGHT / CD258 also binds to a soluble non-signaling receptor, decoy receptor 3 (DcR3), which can modulate the function of LIGHT in vivo. TNFSF14 / LIGHT / CD258 can also costimulate T cell responses via HVEM, which is constitutively expressed in most lymphocyte subpopulations, including CD4+and CD8+T cells. In addition, TNFSF14 / LIGHT / CD258 has been shown to suppress tumor formation in vivo and to induce tumor cell apoptosis via the up-regulation of intercellular adhesion molecule 1 and an increased lymphocyte adhesion to cancer cells. Thus, TNFSF14 / LIGHT / CD258 is being actively investigated as a possible basis for cancer treatment.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy